Why K-Beauty Shipments Get Held at US Customs (8 Failure Modes, 2026)

By the ALTA MEET editorial team | K-beauty ODM consulting

A first-time indie founder shipped 4,800 units of a snail-mucin toner from her Korean ODM to Long Beach in April. Three days after arrival, she received an FDA Hold notification. Five business days later, without the paperwork the port wanted, the shipment escalated to a formal Detention. Ten days after that it was refused admission and had to be re-exported at her cost. The formulation was fine. The safety data was fine. What broke was the paperwork stack that sits underneath every cosmetic import into the United States, and the fact that no one on her Korean side had told her the responsible person on the label was her, not the ODM.

Since the Modernization of Cosmetics Regulation Act of 2022 (MoCRA) began full enforcement, that scenario has moved from unusual to routine. FDA and Customs and Border Protection are now catching cosmetic entries at the same review depth as food and drug entries, and Korean-origin skincare is inside the active enforcement window. This guide walks through the eight failure modes that account for the majority of K-beauty import holds we track from public FDA and CBP records, plus the timeline you get to respond and the pre-flight checklist that keeps most of them from happening.

What Actually Happens When a K-Beauty Shipment Gets Held at US Customs?

An FDA import hold is an electronic flag placed on a shipment during Entry Review, usually within 24 to 48 hours of the container's arrival at a US port of entry. The shipment cannot leave bonded storage until the importer submits documentation clearing the flag. If the paperwork is not submitted within about five business days, the hold escalates to a formal Detention Notice. If the Detention is not cleared, the shipment is refused admission and must be either re-exported or destroyed at the importer's expense.

Entry Review is a defined FDA process. The agency's Entry Review page describes it as "the initial electronic review of FDA-regulated products offered for import" (FDA, Entry Review). Cosmetics entries now flow through this same review pipeline. Under the 2025 SERIO+ (System for Entry Review and Import Operations) upgrade, more of the review is automated, which means more cosmetic entries are getting flagged than in the pre-MoCRA era.

Which Regulatory Bodies Actually Inspect Korean Cosmetic Imports?

Two federal agencies act on cosmetic imports at the US border. Customs and Border Protection (CBP) processes the physical entry, collects duties, and enforces trade laws. The Food and Drug Administration (FDA) reviews the cosmetic-specific compliance stack: facility registration, product listing, labeling, ingredient legality, and GMP posture. In practice, CBP flags the shipment on FDA's behalf and holds it in bonded storage until FDA either releases or refuses it.

For Korean-origin cosmetics, this two-agency model matters because a fully compliant CBP entry is not enough. You can pay the correct tariff, file the correct HTS code, and still be held by FDA for a MoCRA facility registration gap or a labeling issue that CBP never touches. Founders who work only with a customs broker and skip a cosmetics-specific compliance review discover this at the port.

What Are the 8 Failure Modes That Trigger K-Beauty Import Holds?

Failure modes cluster into three families: registration and listing gaps, labeling and claims problems, and ingredient or facility-quality issues. Public FDA guidance and post-MoCRA industry commentary consistently name the same set of triggers (Crowell & Moring on MoCRA final guidance; FDA compliance policy on facility registration and product listing).

Failure Mode 1: The Korean ODM facility is not registered under MoCRA. Every manufacturing facility that produces a cosmetic product for the US market must register with FDA under MoCRA and receive an FDA Establishment Identifier (FEI). Registration renews every two years. If your Korean ODM has not filed Form FDA 5066 or its FEI is expired, the responsible person's product listing cannot resolve to a valid facility, and the shipment fails Entry Review on the first electronic check (FDA Cosmetics Importers).

Failure Mode 2: The responsible person has not filed a product listing. Product listing is Form FDA 5067, filed through the Cosmetics Direct portal by the responsible person, who is the brand whose name appears on the label. This is almost always the indie founder, not the Korean ODM. It must include the facility's FEI and the full ingredient list in Structured Product Labeling (SPL) format, and it must be updated yearly. Founders who assume "the ODM handles listing" discover the listing was never filed when the entry is flagged.

Failure Mode 3: The label carries drug-like claims. Since MoCRA enforcement ramped up, FDA has been strict about efficacy language that crosses the cosmetic-drug line. Claims like "anti-inflammatory," "eczema care," "treats acne," "reduces wrinkles clinically proven to," or "restores DNA" push the product into drug territory and trigger detention. Korean marketing culture tends toward stronger clinical language than what US law allows on a cosmetic label, so the label copy that ships fine domestically in Seoul often fails at US Entry Review. FDA has issued warning letters to cosmetic brands for functional claims that would be unremarkable on a KFDA-registered general cosmetic.

Failure Mode 4: An ingredient is prohibited or restricted for US cosmetic use. Two categories dominate: color additives and specific banned or restricted actives. Color additives, except for coal tar hair dyes, are subject to FDA pre-approval before use in cosmetics, and color additive violations are a common reason for detaining imported cosmetic products (FDA Color Additives and Cosmetics fact sheet). A Korean tinted product that uses a color permitted in KFDA but not FDA-listed for the intended use case will fail. The same applies to a small number of ingredients that MFDS permits at low concentrations but FDA restricts or prohibits.

Failure Mode 5: The label is missing responsible person contact information. Under MoCRA, cosmetic labels must include the domestic responsible person's name and a US contact address that can receive serious adverse event reports. A Korean-origin product that ships with only the Korean manufacturer's Seoul address, or only the brand's website URL, fails label review. This is one of the easiest failures to prevent and also one of the most common because Korean ODMs default to their own label templates.

Failure Mode 6: The declared ingredient list does not match the MFDS-registered formula. When the customs entry ingredient declaration diverges from what the MFDS-registered manufacturing formula lists, or from what the product listing on file with FDA lists, Entry Review flags the mismatch. Common causes include a mid-run formulation tweak the ODM did not push into the export documentation, or a translation error in the INCI-to-Korean ingredient mapping. Every ingredient list touching a US shipment must match every other one exactly.

Failure Mode 7: The Prior Notice or OASIS entry data does not match the customs entry. The FDA Entry Review process compares the electronic entry submitted through OASIS with the physical shipment and the responsible person's on-file registration and listing data. Documentation errors, incorrect FDA product classification, or data mismatches between the entry and the on-file records are among the most frequent triggers for cosmetic holds. Late or incorrect Prior Notice submissions are a common cause of shipment holds and refusals.

Failure Mode 8: The manufacturing facility is GMP-deficient under ISO 22716. As of December 2025, all cosmetics facilities supplying the US market are required to follow FDA GMP requirements harmonized with ISO 22716. If the Korean ODM has not completed a compliant ISO 22716 certification, or has recent audit findings that surfaced through FDA's information-sharing arrangements with international regulators, the facility may sit on an internal FDA watch list. A watch-listed facility's shipments face heavier Entry Review scrutiny and higher hold rates.

How Fast Do You Have to Respond to an FDA Hold?

The response window is tight. Once FDA issues a Hold, you typically have five business days to submit the documentation the port is asking for before the hold escalates to a formal Detention Notice. Once Detention is issued, you have a further limited window to submit evidence supporting release before the shipment is refused admission. Refusal is close to final; the shipment must be re-exported or destroyed, and the reason enters the importer's FDA history and increases the probability of future holds on your entries.

What Does It Cost When a K-Beauty Shipment Gets Refused?

Cost falls into three structural buckets, and any founder-level cost-math needs to walk each of them rather than reach for a single dollar figure that will not apply to a specific run. The first bucket is direct: bonded storage fees accumulate daily while the shipment sits in port, and demurrage charges apply if the container is not moved within the port's grace window. The second bucket is inventory: refused product is either re-exported (usually back to the Korean ODM warehouse for rework or destruction there) or destroyed at the US port. Neither path recovers the full cost of the goods. The third bucket is downstream: refused entries enter the importer's FDA history and materially raise the probability of holds on future shipments, which compounds through every subsequent import. This third cost is the one indie founders consistently underestimate because it is invisible at the time of the first refusal.

How Can Indie K-Beauty Founders Prevent Customs Holds Before Shipping?

Prevention is a pre-flight checklist run before the ODM ships the container, not a firefighting exercise at the port. The following items map directly to the eight failure modes above and cover the majority of what we see fail.

Confirm the Korean ODM's FDA facility registration is current and the FEI is valid. Ask for a copy of the confirmation, not a verbal assurance. Confirm the product listing has been filed through Cosmetics Direct under the responsible person's account, and that the FEI on the listing matches the FEI on the facility registration. If you are the responsible person (you almost certainly are), verify the listing yourself in the portal.

Rewrite label copy to remove any language that could be classified as a drug claim. Terms to strip include "anti-inflammatory," "treats," "cures," "prevents," "clinically restores," "DNA repair," and disease-name references (eczema, rosacea, acne when used as a treatment claim rather than a general benefit). Have the copy reviewed by a US regulatory consultant who has worked with imported cosmetics before, not just by the ODM's export team.

Cross-check the ingredient list against the FDA color additive regulations and the current FDA cosmetic ingredient prohibitions before finalizing the export INCI. Any color additive without an approved use in your intended product category is a Failure Mode 4 candidate. The MFDS approval alone is not sufficient.

Confirm the label carries the responsible person's US contact information and an address where FDA can send serious adverse event correspondence. This can be the founder's business address; it does not need to be a physical retail location.

Run an INCI reconciliation between the MFDS-registered formula, the FDA product listing on file, and the ingredient declaration on the customs entry. Every character should match. Small translation-driven differences that seem trivial are the ones that trigger Entry Review flags.

File Prior Notice correctly and on time. Confirm the classification code, the responsible person on record, and the shipment details match the on-file registration exactly. If you are working with a customs broker, confirm they understand cosmetics entries specifically; brokers who work mostly with food or apparel often miss cosmetic-specific data fields.

Ask the Korean ODM for evidence of ISO 22716 certification and recent audit status. Facilities with clean audit histories move through Entry Review faster.

I'm Liz, I run altameet from Manhattan, NYC. Most of the customs-hold stories I hear from founders trace back to the same three items in this checklist: an unfiled product listing, a drug-adjacent label claim, and an INCI mismatch between the Korean manufacturing formula and the US declaration. If you want a quick gut-check on whether your Korean ODM has these three items covered before your first container ships, I'll give you fifteen minutes free. Email liz@altameet.com or book a 15-min call.

What Should You Do If Your K-Beauty Shipment Is Already Detained?

If you are inside the response window, the recovery playbook is compressed but real. First, read the exact FDA notice carefully; the reason code narrows what documentation the port needs. Second, contact your customs broker immediately and ask them to escalate to their FDA compliance specialist; not every broker has one, so know before you ship. Third, work with a US-based cosmetics regulatory consultant to prepare the response package; response quality matters more than response speed inside the five-day window. Fourth, if the reason is a facility registration or product listing gap, file the missing item immediately through Cosmetics Direct and provide FDA with the confirmation; some Entry Review reasons clear on evidence of good-faith remediation. Fifth, if the reason is a label issue, ask FDA whether relabeling in bonded storage is permitted; for some product categories it is, and this can turn a refusal into a release with delay.

If you have missed the response window and refusal has been issued, the immediate move is triage on the physical inventory: negotiate with the Korean ODM about whether re-export back to the origin facility is workable (some ODMs will accept refused product for rework; some will not), or arrange US-port destruction if re-export costs exceed the recoverable value. Then work with a cosmetics regulatory consultant to close the underlying failure mode before the next shipment moves.

Are There Small Business Exemptions Under MoCRA?

Yes, but the exemption is narrower than founders often assume. If the average gross annual sales of your cosmetic products in the United States over the past three years are under one million dollars, your business may be exempt from certain MoCRA requirements, specifically facility registration, product listing, and full GMP compliance. Adverse event reporting, safety substantiation, and labeling requirements still apply. A first-year indie founder can often qualify for the small business exemption at launch, but the exemption ends the moment sales cross the threshold, and there is no grace period for filing the previously exempted items. Founders on a growth trajectory should file registration and listing before crossing the threshold rather than after.

Key Takeaways

1. FDA Entry Review flags cosmetic shipments within 24 to 48 hours of arrival; the response window before Detention is around five business days.
2. The majority of K-beauty holds trace to eight failure modes concentrated in three families: registration and listing gaps, labeling and claims problems, and ingredient or facility issues.
3. The responsible person on the label is almost always the indie brand, not the Korean ODM, and the responsible person owns the product listing filing under MoCRA.
4. Drug-adjacent claim language that is normal on a KFDA-registered general cosmetic often triggers Entry Review at US ports.
5. Color additive violations and INCI mismatches between the MFDS formula and the US declaration are recurring triggers that a pre-flight checklist can catch.
6. Refused entries flag the importer's FDA history and raise hold rates on future shipments, a downstream cost that compounds.
7. The small business exemption covers registration, listing, and GMP up to one million dollars in US sales but leaves labeling and adverse event reporting in place.

Frequently Asked Questions

Does my Korean ODM handle the FDA product listing for me? Usually no. The product listing under MoCRA is filed by the responsible person, which is the brand whose name appears on the label. That is almost always the indie founder, not the Korean manufacturer. The Korean ODM is responsible for the facility registration on its own factory, but the founder owns the product listing filing. Verify who filed what before shipping.

Can I fix a K-beauty label after it is already in the US? Sometimes. FDA occasionally permits relabeling in bonded storage for label-only deficiencies, but not for claims-based deficiencies or ingredient issues. If your hold reason is a missing responsible person address, relabeling may be viable; if the reason is a drug-adjacent claim, the corrective action is typically a re-export and relabel at origin.

How long does an FDA hold usually take to clear? A hold cleared with clean documentation typically resolves in three to seven business days. A hold that escalates to Detention and then clears with a full evidence package typically takes two to four weeks. A hold that ends in refusal ends the transit entirely and starts the re-export or destruction clock.

Do I need a US agent for MoCRA compliance if my Korean ODM already has one? The Korean facility needs a US agent for its facility registration under MoCRA. Your brand, as the responsible person filing the product listing, uses its own US contact address on the label. These are two separate obligations. Assuming the ODM's US agent covers your brand's responsible person duties is a common early-stage mistake.

What is the fastest way to check if my Korean ODM is compliant before I sign? Ask for three documents in writing: the current FDA facility registration confirmation with FEI, the current ISO 22716 certification, and a recent third-party GMP audit summary. If any of the three is missing or the ODM cannot produce them within a week, treat that as material information for your sourcing decision.

Working With Us

ALTA MEET runs pre-shipment compliance reviews for indie K-beauty brands moving from Korean ODM manufacturing to US market entry. If you have a first container coming through Long Beach or Newark and want a second pair of eyes on the registration, listing, and label stack before the ship leaves Busan, email Liz at liz@altameet.com or book a 15-minute gut-check call. For general partnership inquiries, reach us at partnerships@altameet.com.

Related reading: How to Import Korean Cosmetics to the USA: Costs, Customs, and Compliance (2026) · KFDA vs FDA vs EU: Cosmetic Safety Standards for K-Beauty Brands (2026) · FDA & MoCRA Compliance for Korean Skincare Imports (2026) · Korean ODM Compliance Documents for US, EU, and UK Launch (2026)

Reviewed for accuracy by ALTA MEET's regulatory consulting team. Sources: FDA Entry Review, FDA Cosmetics Importers, FDA Import Alerts, FDA MoCRA facility registration and product listing compliance policy, Crowell & Moring on FDA MoCRA final guidance, FDA Color Additives and Cosmetics fact sheet, FDA Cosmetics & U.S. Law.